Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders

Bibliography

• Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988;240(4849):219-21
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su T-P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007;131(3):596-610
   PubMed Web of Science ®Google Scholar
• Mori T, Hayashi T, Hayashi E, Su T-P. Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. PLoS One 2013;8(10):e76941
   PubMed Web of Science ®Google Scholar
• Tsai S-Y, Hayashi T, Harvey BK, et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1·GTP pathway. Proc Natl Acad Sci USA 2009;106(52):22468-73
   Google Scholar
• Tsai S-Y, Rothman RK, Su T-P. Insights into the Sigma-1 receptor chaperone’s cellular functions: a microarray report. Synapse 2012;66(1):42-51
   PubMed Web of Science ®Google Scholar
• Pal A, Fontanilla D, Gopalakrishnan A, et al. The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol 2012;682(1-3):12-20
   PubMed Web of Science ®Google Scholar
• Katz JL, Su T-P, Hiranita T, et al. A role for sigma receptors in stimulant self administration and addiction. Pharmaceuticals (Basel) 2011;4(6):880-914
   PubMedGoogle Scholar
• Kourrich S, Hayashi T, Chuang J-Y, et al. Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine. Cell 2013;152(1-2):236-47
   Google Scholar
• Su T-P, Hayashi T, Maurice T, et al. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci 2010;31(12):557-66
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9(11):617-28
   PubMed Web of Science ®Google Scholar
• Fecto F, Siddique T. SIGMAR1 mutations, genetic heterogeneity at the chromosome 9p locus, and the expanding etiological diversity of amyotrophic lateral sclerosis. Ann Neurol 2011;70(6):867-70
   Google Scholar
• Iguchi Y, Katsuno M, Ikenaka K, et al. Amyotrophic lateral sclerosis: an update on recent genetic insights. J Neurol 2013;260(11):2917-27
   Google Scholar
• Luty AA, Kwok JB, Dobson-Stone C, et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol 2010;68(5):639-49
   PubMed Web of Science ®Google Scholar
• Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol 2011;70(6):913-19
   PubMed Web of Science ®Google Scholar
• Tagashira H, Shinoda Y, Shioda N, et al. Methyl pyruvate rescues mitochondrial damage caused by SIGMAR1 mutation related to amyotrophic lateral sclerosis. Biochim Biophys Acta 2014;1840(12):3320-34
   Google Scholar
• Belzil VV, Daoud H, Camu W, et al. Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. Eur J Hum Genet 2013;21(2):237-9
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hayashi E, Fujimoto M, et al. The lifetime of UDP-galactose:ceramide galactosyltransferase is controlled by a distinct endoplasmic reticulum-associated degradation (ERAD) regulated by sigma-1 receptor chaperones. J Biol Chem 2012;287(51):43156-69
   Google Scholar
• Gromek KA, Suchy FP, Meddaugh HR, et al. The oligomeric states of the purified sigma 1 receptor are stabilized by ligands. J Biol Chem 2014;289(29):20333-44
   PubMed Web of Science ®Google Scholar
• Miki Y, Mori F, Kon T, et al. Accumulation of the sigma-1 receptor is common to neuronal nuclear inclusions in various neurodegenerative diseases. Neuropathology 2014;34(2):148-58
   Google Scholar
• Alonso G, Phan V, Guillemain I, et al. Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system. Neuroscience 2000;97(1):155-70
   PubMed Web of Science ®Google Scholar
• Mavlyutov TA, Epstein ML, Andersen KA, et al. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience 2010;167(2):247-55
   PubMed Web of Science ®Google Scholar
• Mavlyutov TA, Epstein ML, Liu P, et al. Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N,N’-dimethyltryptamine forming enzyme, indole-N-methyl transferase. Neuroscience 2012;206:60-8
   Google Scholar
• Casas C, Herrando-Grabulosa M, Manzano R, et al. Early presymptomatic cholinergic dysfunction in a murine model of amyotrophic lateral sclerosis. Brain Behav 2013;3(2):145-58
   Google Scholar
• Mancuso R, Oliván S, Rando A, et al. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics 2012;9(4):814-26
   PubMed Web of Science ®Google Scholar
• Mavlyutov TA, Epstein ML, Verbny YI, et al. Lack of sigma-1 receptor exacerbates ALS progression in mice. Neuroscience 2013;240:129-34
   PubMed Web of Science ®Google Scholar
• Ono Y, Tanaka H, Takata M, et al. SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models. Neurosci Lett 2014;559:174-8
   PubMed Web of Science ®Google Scholar
• Prause J, Goswami A, Katona I, et al. Altered localization, abnormal modification and loss of function of sigma receptor-1 in amyotrophic lateral sclerosis. Hum Mol Genet 2013;22(8):1581-600
   PubMed Web of Science ®Google Scholar
• Peviani M, Salvaneschi E, Bontempi L, et al. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiol Dis 2014;62:218-32
   PubMed Web of Science ®Google Scholar
• Mancuso R, Del Valle J, Morell M, et al. Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity? Orphanet J Rare Dis 2014;9:78
   PubMed Web of Science ®Google Scholar
• Thies W, Bleiler L. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 2013;9(2):208-45
   PubMed Web of Science ®Google Scholar
• Price JL, McKeel DW, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30(7):1026-36
   PubMed Web of Science ®Google Scholar
• Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000;21:383-421
   PubMed Web of Science ®Google Scholar
• Maurice T, Su T-P. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009;124(2):195-206
   PubMed Web of Science ®Google Scholar
• Hayashi T, Tsai S-Y, Mori T, et al. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 2011;15(5):557-77
   PubMed Web of Science ®Google Scholar
• Hedskog L, Pinho CM, Filadi R, et al. Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer’s disease and related models. Proc Natl Acad Sci USA 2013;110(19):7916-21
   Google Scholar
• Mishina M, Ohyama M, Ishii K, et al. Low density of sigma1 receptors in early Alzheimer’s disease. Ann Nucl Med 2008;22(3):151-6
   PubMed Web of Science ®Google Scholar
• Maruszak A, Safranow K, Gacia M, et al. Sigma receptor type 1 gene variation in a group of polish patients with Alzheimer’s disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:432-8
   PubMed Web of Science ®Google Scholar
• Fehér Á, Juhász A, László A, et al. Association between a variant of the sigma-1 receptor gene and Alzheimer’s disease. Neurosci Lett 2012;517(2):136-9
   PubMed Web of Science ®Google Scholar
• Mrak RE. Neuropathology and the neuroinflammation idea. J Alzheimers Dis 2009;18(3):473-81
   Google Scholar
• Behensky AA, Yasny IE, Shuster AM, et al. Afobazole activation of sigma-1 receptors modulates neuronal responses to amyloid-beta25-35. J Pharmacol Exp Ther 2013;347(2):468-77
   Google Scholar
• Maurice T, Su T-P, Privat A. Sigma1 receptor agonists and neurosteroids attenuate beta25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 1998;83(2):413-28
   PubMed Web of Science ®Google Scholar
• Mori T, Hayashi T, Su T-P. Compromising sigma-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-κB/Bcl-2-dependent mechanism: potential relevance to Parkinson’s disease. J Pharmacol Exp Ther 2012;341(3):663-71
   PubMed Web of Science ®Google Scholar
• Solntseva EI, Kapai NA, Popova O V, et al. The involvement of sigma1 receptors in donepezil induced rescue of hippocampal LTP impaired by beta-amyloid peptide. Brain Res Bull 2014;106:56-61
   PubMed Web of Science ®Google Scholar
• Brion J-P. Immunological demonstration of tau protein in neurofibrillary tangles of Alzheimer’s disease. J Alzheimers Dis 2006;9(3 Suppl):177-85
   Google Scholar
• Wang Y, Martinez-Vicente M, Krüger U, et al. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet 2009;18(21):4153-70
   PubMed Web of Science ®Google Scholar
• Vollrath JT, Sechi A, Dreser A, et al. Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances. Cell Death Dis 2014;5:e1290
   PubMed Web of Science ®Google Scholar
• Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer’s disease. Science 1987;235(4796):1641-4
   Google Scholar
• David DC, Layfield R, Serpell L, et al. Proteasomal degradation of tau protein. J Neurochem 2002;83(1):176-85
   Google Scholar
• Feuillette S, Blard O, Lecourtois M, et al. Tau is not normally degraded by the proteasome. J Neurosci Res 2005;80(3):400-5
   Google Scholar
• Lahmy V, Meunier J, Malmström S, et al. Blockade of Tau hyperphosphorylation and Abeta1-42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma1 receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology 2013;38(9):1706-23
   PubMed Web of Science ®Google Scholar
• Ishima T, Nishimura T, Iyo M, et al. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(7):1656-9
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Sakata M, Ishii K, et al. High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol 2009;12(8):1127-31
   PubMed Web of Science ®Google Scholar
• Ruscher K, Shamloo M, Rickhag M, et al. The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain 2011;134(Pt 3):732-46
   Google Scholar
• Gekker G, Hu S, Sheng WS, et al. Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-beta1. Int Immunopharmacol 2006;6(6):1029-33
   PubMed Web of Science ®Google Scholar
• Hall AA, Herrera Y, Ajmo CT, et al. Sigma receptors suppress multiple aspects of microglial activation. Glia 2009;57(7):744-54
   PubMed Web of Science ®Google Scholar
• Savica R, Grossardt BR, Bower JH, et al. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol 2013;70(7):859-66
   PubMed Web of Science ®Google Scholar
• Gao H-M, Zhang F, Zhou H, et al. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. Environ Health Perspect 2011;119(6):807-14
   PubMed Web of Science ®Google Scholar
• Sung VW, Nicholas AP. Nonmotor symptoms in Parkinson’s disease: expanding the view of Parkinson’s disease beyond a pure motor, pure dopaminergic problem. Neurol Clin 2013;31(3 Suppl):S1-16
   PubMed Web of Science ®Google Scholar
• Recasens A, Dehay B, Bové J, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014;75(3):351-62
   PubMed Web of Science ®Google Scholar
• Mishina M, Ishiwata K, Ishii K, et al. Function of sigma1 receptors in Parkinson’s disease. Acta Neurol Scand 2005;112(2):103-7
   PubMed Web of Science ®Google Scholar
• Paquette MA, Foley K, Brudney EG, et al. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl) 2009;204(4):743-54
   Google Scholar
• Paquette MA, Brudney EG, Putterman DB, et al. Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. Neuroreport 2008;19(1):111-15
   Google Scholar
• Lesage AS, De Loore KL, Peeters L, et al. Neuroprotective sigma ligands interfere with the glutamate-activated NOS pathway in hippocampal cell culture. Synapse 1995;20(2):156-64
   Google Scholar
• Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S210-12
   PubMed Web of Science ®Google Scholar
• Francardo V, Bez F, Wieloch T, et al. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain 2014;137(Pt 7):1998-2014
   PubMedGoogle Scholar
• Ohi K, Hashimoto R, Yasuda Y, et al. The SIGMAR1 gene is associated with a risk of schizophrenia and activation of the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(5):1309-15
   PubMed Web of Science ®Google Scholar
• Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry 2000;47(3):210-20
   PubMedGoogle Scholar
• Uchida N, Ujike H, Nakata K, et al. No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies. BMC Psychiatry 2003;3:13
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Ishiwata K, Ishii K, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry 2007;62(8):878-83
   PubMed Web of Science ®Google Scholar
• Monnet FP, Morin-Surun MP, Leger J, et al. Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons. J Pharmacol Exp Ther 2003;307(2):705-12
   PubMed Web of Science ®Google Scholar
• Balasuriya D, Stewart AP, Edwardson JM. The sigma-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1/GluN2A NMDA receptor. J Neurosci 2013;33(46):18219-24
   PubMed Web of Science ®Google Scholar
• Iyo M, Shirayama Y, Watanabe H, et al. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(4):1072-3
   Web of Science ®Google Scholar
• Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 2007;32(3):514-21
   Web of Science ®Google Scholar
• Niitsu T, Fujisaki M, Shiina A, et al. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol 2012;32(5):593-601
   Google Scholar
• Trivedi MH, Lin EHB, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr 2007;12(8 Suppl 13):1-27
   PubMed Web of Science ®Google Scholar
• Bremner JD. Does stress damage the brain? Biol Psychiatry 1999;45(7):797-805
   PubMed Web of Science ®Google Scholar
• Kishi T, Yoshimura R, Okochi T, et al. Association analysis of SIGMAR1 with major depressive disorder and SSRI response. Neuropharmacology 2010;58(7):1168-73
   Google Scholar
• Skuza G, Rogóz Z. A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist. Behav Pharmacol 2002;13(7):537-43
   PubMed Web of Science ®Google Scholar
• Ukai M, Maeda H, Nanya Y, et al. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav 1998;61(3):247-52
   PubMed Web of Science ®Google Scholar
• Urani A, Romieu P, Portales-Casamar E, et al. The antidepressant-like effect induced by the sigma(1) (sigma(1)) receptor agonist igmesine involves modulation of intracellular calcium mobilization. Psychopharmacology (Berl) 2002;163(1):26-35
   PubMed Web of Science ®Google Scholar
• Shimizu H, Takebayashi M, Tani M, et al. Sigma-1 receptor concentration in plasma of patients with late-life depression: a preliminary study. Neuropsychiatr Dis Treat 2013;8:1867-72
   Google Scholar
• Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 2005;10(4):319-23
   PubMed Web of Science ®Google Scholar
• Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996;307(1):117-19
   Web of Science ®Google Scholar
• Volz H-P, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry 2004;37(Suppl 3):S214-20
   Google Scholar
• Van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology (Berl) 2003;165(2):97-110
   Google Scholar
• Moriguchi S, Yamamoto Y, Ikuno T, et al. Sigma-1 receptor stimulation by dehydroepiandrosterone ameliorates cognitive impairment through activation of CaM kinase II, protein kinase C and extracellular signal-regulated kinase in olfactory bulbectomized mice. J Neurochem 2011;117(5):879-91
   Google Scholar
• Dhir A, Kulkarni S. Involvement of sigma (sigma1) receptors in modulating the anti-depressant effect of neurosteroids (dehydroepiandrosterone or pregnenolone) in mouse tail-suspension test. J Psychopharmacol 2008;22(6):691-6
   Google Scholar
• Penzes P, Cahill ME, Jones KA, et al. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 2011;14(3):285-93
   PubMed Web of Science ®Google Scholar
• Takebayashi M, Hayashi T, Su T-P. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J Pharmacol Exp Ther 2002;303(3):1227-37
   PubMed Web of Science ®Google Scholar
• Chen Z-Y, Jing D, Bath KG, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006;314(5796):140-3
   PubMed Web of Science ®Google Scholar
• Romieu P, Phan VL, Martin-Fardon R, et al. Involvement of the sigma(1) receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 2002;26(4):444-55
   Google Scholar
• Liu Y, Matsumoto RR. Alterations in fos-related antigen 2 and sigma1 receptor gene and protein expression are associated with the development of cocaine-induced behavioral sensitization: time course and regional distribution studies. J Pharmacol Exp Ther 2008;327(1):187-95
   Google Scholar
• Matsumoto RR, Hewett KL, Pouw B, et al. Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology 2001;41(7):878-86
   PubMed Web of Science ®Google Scholar
• Seminerio MJ, Robson MJ, Abdelazeem AH, et al. Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine. AAPS J 2012;14(1):43-51
   PubMed Web of Science ®Google Scholar
• Rahmadi M, Mori T, Kanazawa M, et al. Involvement of sigma 1 receptor in the SSRI-induced suppression of the methamphetamine-induced behavioral sensitization and rewarding effects in mice. Nihon Shinkei Seishin Yakurigaku Zasshi 2013;33(2):49-56
   Google Scholar
• Sabino V, Cottone P, Blasio A, et al. Activation of sigma-receptors induces binge-like drinking in Sardinian alcohol-preferring rats. Neuropsychopharmacology 2011;36(6):1207-18
   PubMed Web of Science ®Google Scholar
• Nagel BJ, Schweinsburg AD, Phan V, et al. Reduced hippocampal volume among adolescents with alcohol use disorders without psychiatric comorbidity. Psychiatry Res 2005;139(3):181-90
   PubMed Web of Science ®Google Scholar
• Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med 1987;107(6):828-36
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shi Y, Qiao L, et al. Sigma-1 receptor agonists provide neuroprotection against gp120 via a change in bcl-2 expression in mouse neuronal cultures. Brain Res 2012;1431:13-22
   PubMed Web of Science ®Google Scholar
• Yao H, Kim K, Duan M, et al. Cocaine hijacks sigma1 receptor to initiate induction of activated leukocyte cell adhesion molecule: implication for increased monocyte adhesion and migration in the CNS. J Neurosci 2011;31(16):5942-55
   Google Scholar
• Goodkin K, Shapshak P, Metsch LR, et al. Cocaine abuse and HIV-1 infection: epidemiology and neuropathogenesis. J Neuroimmunol 1998;83(1-2):88-101
   PubMed Web of Science ®Google Scholar
• Buch S, Yao H, Guo M, et al. Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms. Curr HIV Res 2012;10(5):425-8
   PubMed Web of Science ®Google Scholar
• Eugenin EA, Osiecki K, Lopez L, et al. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci 2006;26(4):1098-106
   PubMed Web of Science ®Google Scholar
• Tsai S-Y, Hayashi T, Mori T, et al. Sigma-1 receptor chaperones and diseases. Cent Nerv Syst Agents Med Chem 2009;9(3):184-9
   PubMedGoogle Scholar
• Meunier J, Hayashi T. Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. J Pharmacol Exp Ther 2010;332(2):388-97
   PubMed Web of Science ®Google Scholar
• Wager K, Russell C. Mitophagy and neurodegeneration: the zebrafish model system. Autophagy 2013;9(11):1693-709
   PubMed Web of Science ®Google Scholar
• Jiang P, Mizushima N. Autophagy and human diseases. Cell Res 2014;24(1):69-79
   PubMed Web of Science ®Google Scholar
• Wang H-H, Chien J-W, Chou Y-C, et al. Anti-amnesic effect of dimemorfan in mice. Br J Pharmacol 2003;138(5):941-9
   Google Scholar
• Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 2006;149(8):998-1012
   PubMed Web of Science ®Google Scholar
• Kunitachi S, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res 2009;1279:189-96
   PubMed Web of Science ®Google Scholar
• Albayrak Y, Hashimoto K. Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases. Prim Care Companion CNS Disord 2012;14:6
   Google Scholar
• Frieboes RM, Murck H, Wiedemann K, et al. Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology (Berl) 1997;132(1):82-8
   PubMed Web of Science ®Google Scholar
• Yang R, Chen L, Wang H, et al. Anti-amnesic effect of neurosteroid PREGS in Abeta25-35-injected mice through sigma1 receptor- and alpha7nAChR-mediated neuroprotection. Neuropharmacology 2012;63(6):1042-50
   Google Scholar
• Antonini V, Marrazzo A, Kleiner G, et al. Anti-amnesic and neuroprotective actions of the sigma-1 receptor agonist (-)-MR22 in rats with selective cholinergic lesion and amyloid infusion. J Alzheimers Dis 2011;24(3):569-86
   PubMed Web of Science ®Google Scholar
• Hyrskyluoto A, Pulli I, Törnqvist K, et al. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway. Cell Death Dis 2013;4:e646
   PubMed Web of Science ®Google Scholar
• Maurice T, Phan VL, Urani A, et al. Differential involvement of the sigma(1) (sigma(1)) receptor in the anti-amnesic effect of neuroactive steroids, as demonstrated using an in vivo antisense strategy in the mouse. Br J Pharmacol 2001;134(8):1731-41
   Google Scholar
• Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol 2014;727:167-73
   PubMed Web of Science ®Google Scholar